StackItSmart

Compound reference

Raloxifene

Evista

Ancillary compounds3 cited findingsClinical review: not reviewed

Clinical & experimental findings

Human randomized studyAbstract inspected

The MORE/CORE program reported fewer invasive estrogen-receptor-positive breast cancers with raloxifene in postmenopausal women with osteoporosis (66% fewer over 8 combined years). It also reported a thromboembolism signal during CORE (relative risk 2.17) whose confidence interval (0.83-5.70) crossed 1; this does not establish male gynecomastia or post-AAS recovery efficacy.[1]

  • Continuation cohort selection; no male recovery study; the CORE thromboembolism confidence interval (0.83-5.70) crosses 1 and is not statistically significant on its own.
  • Abstract-checked; full paper not confirmed open access as of 2026-09-09. No qualified clinical review.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Independent source inspection; applicability narrowed and inherited assertions excluded where unsupported. No qualified clinical review.

· Reopened the abstract on 2026-09-09; verified the exact hazard ratios/CIs and added the 8-year combined figure and the precise thromboembolism CI to the claim text.

Interaction evidence

Mechanistic inferenceAbstract inspected

Breast-cancer prevention trials found more thromboembolic events with individual SERMs including tamoxifen and raloxifene. Whether combining the two further increases that risk is unquantified.[2]

  • Trials in women; no dual-SERM trial and no evidence for a recovery regimen.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Supporting passages inspected, scope corrected and legacy assertions reassessed; no clinician review performed.

· Independently reopened every cited source afresh on 2026-09-09 (interaction batch, fresh deep-research pass); disposition and wording reconfirmed against the live sources, not carried over from the prior pass. No qualified clinical review.

Mechanistic inferenceAbstract inspected

Testosterone-related hematocrit increases and tamoxifen/raloxifene thromboembolic findings come from different study populations. They motivate a possible overlapping concern, not evidence of a measured thrombosis increase from the selected pair.[3][2]

  • This evidence does not establish the magnitude or frequency of harm from the selected combination.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Supporting passages inspected, scope corrected and legacy assertions reassessed; no clinician review performed.

· Independently reopened every cited source afresh on 2026-09-09 (interaction batch, fresh deep-research pass); disposition and wording reconfirmed against the live sources, not carried over from the prior pass. No qualified clinical review.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Narrowly supported passages published with study/product limits; remaining inherited assertions withheld from established-fact displays.

  • Not a comprehensive systematic review. Original monograph topics beyond the individual published claims—including monitoring schedules, contraindication lists, recovery assurances and detailed mechanisms—remain unverified.
  • No qualified clinician has reviewed these claims. Long-term outcomes and all marketed formulations have not been fully assessed.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

  1. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

    2004-12-01. PMID:15572757 · DOI:10.1093/jnci/djh319 Abstract only.

    Inspected location: PubMed abstract: full Results (CORE: invasive breast cancer -59% [HR 0.41, 95% CI 0.24-0.71], ER-positive invasive -66% [HR 0.34, 95% CI 0.18-0.66]; 8-year combined MORE+CORE: -66% [HR 0.34, 95% CI 0.22-0.50] and -76% [HR 0.24, 95% CI 0.15-0.40]; thromboembolism relative risk 2.17, 95% CI 0.83-5.70) and Methods (n=3510 raloxifene, n=1703 placebo continuers)

    Study context and inspection record
  2. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

    2013-05-25. PMID:23639488 Abstract only.

    Inspected location: PubMed abstract; publication types and CommentsCorrections in NLM EFetch XML

    Study context and inspection record
  3. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis

    2010-06. PMID:20525906 Abstract only.

    Inspected location: PubMed abstract; publication types and CommentsCorrections in NLM EFetch XML

    Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts
  • Fresh PubMed EUtils retrieval for inherited lead PMID 15572757; identity, abstract and linked corrections checked where an abstract existed.
  • https://pubmed.ncbi.nlm.nih.gov/15572757/ — abstract; PubMed abstract: Results: invasive estrogen-receptor-positive breast cancer and thromboembolism during MORE/CORE

View this compound in the research library →

Related records in this class

Grouped under Ancillary compounds for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.

StackItSmart

Age confirmation

This reference discusses steroids, SARMs and other compounds. It is educational, not medical advice, and does not recommend using or combining them.

Your confirmation is saved in this browser when storage is available.